Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

COVID-19 initially reduced asthma attacks but widened socioeconomic disparities, study finds

25

Feb 2026

COVID-19 initially reduced asthma attacks but widened socioeconomic disparities, study finds

A large retrospective study of more than 162,000 asthma patients in the Bronx found that asthma exacerbations dropped sharply after the onset of COVID-19 before rebounding in children but remaining lower in adults. Socioeconomic disparities widened during the pandemic, particularly among Medicaid recipients, certain income groups, and patients with documented unmet social needs, while racial and ethnic gaps persisted without significantly expanding.

Meningococcal B vaccine fails to prevent gonorrhea, trial shows

25

Feb 2026

Meningococcal B vaccine fails to prevent gonorrhea, trial shows

Contrary to existing evidence from observational studies, the meningococcal B vaccine (4CMenB) has no effect on preventing the acquisition of gonorrhea, according to the results of the world's largest randomized control trial (RCT) into possible efficacy, conducted by Griffith University's Institute for Biomedicine and Glycomics and the Kirby Institute at UNSW Sydney.

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

25

Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

Long-term cola intake weakens immune cell counts in controlled rat study

25

Feb 2026

Long-term cola intake weakens immune cell counts in controlled rat study

Replacing drinking water entirely with sugar-sweetened or sugar-free cola for eight weeks altered gut microbiota composition and immune-related indices in rats, despite no changes in body weight or blood glucose. Both beverages were associated with leukocyte reductions and organ-related biochemical shifts, with sugar-sweetened cola more strongly linked to renal markers and diet cola to elevated liver enzymes.

Having “hasslers” in your network linked to faster aging and poorer health

25

Feb 2026

Having “hasslers” in your network linked to faster aging and poorer health

Researchers analyzed a state-representative US sample to examine whether negative social ties, termed “hasslers,” are associated with epigenetic age acceleration and faster biological aging. Each additional hassler was linked to roughly nine months higher biological age and a 1.5% faster pace of aging, with particularly strong associations for mental health outcomes.

Could a rare gene variant help reduce smoking? New study suggests it might

25

Feb 2026

Could a rare gene variant help reduce smoking? New study suggests it might

An exome-wide association study of nearly 38,000 smokers from the Mexico City Prospective Study identified rare coding variants in CHRNB3 that are associated with substantially fewer cigarettes smoked per day. Cross-ancestry analyses in European and East Asian datasets support a role for the β3 nicotinic receptor subunit in modulating smoking intensity.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.